SC-43 is widely used in research settings for its potent inhibitory effects on the STAT3 signaling pathway, which plays a critical role in cancer cell proliferation and survival. It has demonstrated promising anti-tumor activity, particularly in hepatocellular carcinoma and other solid tumors, by inducing apoptosis and suppressing tumor growth in preclinical models. Due to its ability to overcome resistance to sorafenib, SC-43 is being investigated as a potential therapeutic agent in resistant cancer types. It is also employed as a tool compound to study JAK/STAT signaling mechanisms in cellular and molecular biology research. Its application remains restricted to laboratory and experimental studies, with no current clinical use in humans.